◀ Back to EPHB2

EPHB2 — PAM

Text-mined interactions from Literome

Slack et al., Eur J Immunol 2007 : Conversely, ERK activation in response to the TLR2 agonist Pam3Cys is completely MyD88 dependent and unaffected by Syk deficiency
Adhikary et al., J Leukoc Biol 2008 (Corneal Diseases...) : We found that S. aureus and Pam3Cys stimulate phosphorylation of JNK, p38 MAPK, and ERK within 4 h and that blockade of JNK, but not p38 or ERK phosphorylation, had an inhibitory effect on IkBalpha degradation and CXC chemokine production
Nyugen et al., J Clin Immunol 2010 (Bacterial Infections) : In this study, we have identified and compared four subpopulations of monocytes ( CD14 ( ++ ( high ) ) CD16 ( - ), CD14 ( + ( low ) ) CD16 ( - ), CD14 ( ++ ( high ) ) CD16 ( + ), and CD14 ( + ( low ) ) CD16 ( + ) ) in the peripheral blood of young and aged subjects with regard to their numbers, cytokine production, TLR expression, and phosphorylation of ERK1/2 in response to pam3Cys a TLR-1/2 ligand
Beaulieu et al., Blood 2011 : Using Meg-01 cells and mouse megakaryocytes, we found that NF?B, ERK-MAPK , and PI3K/Akt pathways, known downstream pathways of TLRs, are activated by Pam3CSK4 , a TLR2-specific ligand
Foley et al., J Biol Chem 2012 (MAP Kinase Signaling System) : Pam3Cys , a specific TLR2 agonist, stimulated phosphorylation of JNK, ERK , and p38, but only JNK and ERK inhibition blocked Pam3Cys stimulated chemotaxis